Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:PNT

POINT Biopharma Global (PNT) Stock Price, News & Analysis

POINT Biopharma Global logo

About POINT Biopharma Global Stock (NASDAQ:PNT)

Key Stats

Today's Range
N/A
50-Day Range
$12.45
$14.23
52-Week Range
N/A
Volume
3.29 million shs
Average Volume
1.44 million shs
Market Capitalization
$1.33 billion
P/E Ratio
13.89
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive PNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for POINT Biopharma Global and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PNT Stock News Headlines

October 16 Changes the Microchip Game — and Investing
While everyone's chasing the same AI plays, George Gilder is focused on something completely different. He says a 4-nanometer device that's 80 MILLION times more powerful than the chip he gave Reagan is now being made in America for the first time. And he's identified 3 companies that control this technology.tc pixel
Lilly Completes Acquisition of POINT Biopharma
See More Headlines

PNT Stock Analysis - Frequently Asked Questions

POINT Biopharma Global Inc. (NASDAQ:PNT) posted its earnings results on Monday, November, 13th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.07. The firm earned $2.79 million during the quarter, compared to the consensus estimate of $8 million. POINT Biopharma Global had a trailing twelve-month return on equity of 21.10% and a net margin of 39.62%.

Based on aggregate information from My MarketBeat watchlists, some other companies that POINT Biopharma Global investors own include NVIDIA (NVDA), Broadcom (AVGO), Novo Nordisk A/S (NVO), Disc Medicine (IRON), Arista Networks (ANET), e.l.f. Beauty (ELF) and Builders FirstSource (BLDR).

Company Calendar

Last Earnings
11/13/2023
Today
10/18/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PNT
CIK
1811764
Fax
N/A
Employees
129
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
$0.90
Trailing P/E Ratio
13.89
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$98.29 million
Net Margins
39.62%
Pretax Margin
52.16%
Return on Equity
21.10%
Return on Assets
18.28%

Debt

Debt-to-Equity Ratio
0.01
Current Ratio
9.14
Quick Ratio
9.14

Sales & Book Value

Annual Sales
$226.58 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
13.31
Book Value
$4.68 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
106,570,000
Free Float
89,518,000
Market Cap
$1.33 billion
Optionable
Optionable
Beta
N/A
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:PNT) was last updated on 10/18/2025 by MarketBeat.com Staff
From Our Partners